Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Puig

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
The British Journal of Dermatology|January 6, 2025
Postswitching discontinuation of biosimilars in psoriasis: registry analyses fall short in addressing real-world biasesLuis Puig
The Journal of Investigative Dermatology|August 5, 2025
Repurposing Roflumilast and the Emerging Landscape of Phosphodiesterase 4 Inhibition in PsoriasisLuis Puig
Lancet (London, England)|September 21, 2025
Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacyLuis Puig
American Journal of Clinical Dermatology|April 12, 2020
Managing Cutaneous Immune-Mediated Diseases During the COVID-19 PandemicTiago Torres, Luis Puig
American Journal of Clinical Dermatology|June 10, 2017
Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic ArthritisTiago Torres, Luis Puig
Dermatology and Therapy|August 8, 2025
Letter to the Editor Regarding: "Cardiovascular and Kidney Outcomes After Systemic Treatment for Plaque Psoriasis: A Systematic Review and Network Meta‑Analysis"Tiago Torres, Luis Puig
International Journal of Molecular Sciences|February 25, 2023
Tyk2 Targeting in Immune-Mediated Inflammatory DiseasesLluís Rusiñol, Luis Puig
American Journal of Clinical Dermatology|October 27, 2021
Authors' reply to Borg and Thoning: "Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study"Tiago Torres, Andrea Chiricozzi, Luis Puig
Current Treatment Options in Oncology|May 1, 2020
The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma : Epithelial-to-Mesenchymal Transition in Cutaneous SCCMaria-Teresa Fernandez-Figueras, Luis Puig
Drugs|February 6, 2020
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 InhibitorsMiguel Nogueira, Luis Puig, Tiago Torres
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
The British Journal of Dermatology|January 6, 2025
Postswitching discontinuation of biosimilars in psoriasis: registry analyses fall short in addressing real-world biasesLuis Puig
The Journal of Investigative Dermatology|August 5, 2025
Repurposing Roflumilast and the Emerging Landscape of Phosphodiesterase 4 Inhibition in PsoriasisLuis Puig
Lancet (London, England)|September 21, 2025
Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacyLuis Puig
American Journal of Clinical Dermatology|April 12, 2020
Managing Cutaneous Immune-Mediated Diseases During the COVID-19 PandemicTiago Torres, Luis Puig
American Journal of Clinical Dermatology|June 10, 2017
Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic ArthritisTiago Torres, Luis Puig
Dermatology and Therapy|August 8, 2025
Letter to the Editor Regarding: "Cardiovascular and Kidney Outcomes After Systemic Treatment for Plaque Psoriasis: A Systematic Review and Network Meta‑Analysis"Tiago Torres, Luis Puig
International Journal of Molecular Sciences|February 25, 2023
Tyk2 Targeting in Immune-Mediated Inflammatory DiseasesLluís Rusiñol, Luis Puig
American Journal of Clinical Dermatology|October 27, 2021
Authors' reply to Borg and Thoning: "Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study"Tiago Torres, Andrea Chiricozzi, Luis Puig
Current Treatment Options in Oncology|May 1, 2020
The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma : Epithelial-to-Mesenchymal Transition in Cutaneous SCCMaria-Teresa Fernandez-Figueras, Luis Puig
Drugs|February 6, 2020
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 InhibitorsMiguel Nogueira, Luis Puig, Tiago Torres
Pageof 13